

Cite this: *Chem. Sci.*, 2018, **9**, 646

The price of flexibility – a case study on septanooses as pyranose mimetics†

Christoph P. Sager, Brigitte Fiege, Pascal Zihlmann, Raghu Vannam, Said Rabbani, ^a Roman P. Jakob, Roland C. Preston, ^a Adam Zalewski, Timm Maier, Mark W. Peczuh *^b and Beat Ernst *^a

Seven-membered ring mimetics of mannose were studied as ligands for the mannose-specific bacterial lectin FimH, which plays an essential role in the first step of urinary tract infections (UTI). A competitive binding assay and isothermal titration calorimetry (ITC) experiments indicated an approximately ten-fold lower affinity for the seven-membered ring mannose mimetic 2-O-*n*-heptyl-1,6-anhydro-D-glycero-D-galactitol (7) compared to *n*-heptyl α -D-mannopyranoside (2), resulting exclusively from a loss of conformational entropy. Investigations by solution NMR, X-ray crystallography, and molecular modeling revealed that 7 establishes a superimposable H-bond network compared to mannoseide 2, but at the price of a high entropic penalty due to the loss of its pronounced conformational flexibility. These results underscore the importance of having access to the complete thermodynamic profile of a molecular interaction to "rescue" ligands from entropic penalties with an otherwise perfect fit to the protein binding site.

Received 2nd October 2017
Accepted 7th November 2017

DOI: 10.1039/c7sc04289b
rsc.li/chemical-science

Introduction

The flexibility of a molecule defines its intrinsic conformational entropy. Rigid molecules adopt a highly populated conformational ground state with no or only a few alternative conformations. In contrast, flexible molecules populate multiple conformers with low barriers for interconversion between them. Flexibility has implications on intermolecular interactions in different manners (Fig. 1).¹ Emil Fischer's lock-and-key model (A) assumes two rigid partners and therefore requires precise complementary shapes to allow tight binding.^{2–6} However, in most cases, either the ligand (B)^{7–12} or the receptor (C)^{13,14} exhibits flexibility while its binding partner is rather rigid. In these cases, complex formation requires an induced fit⁵ or a conformational selection mechanism.^{15–18} Finally, considerable reorganizational energy is required for interactions in which both ligand and receptor are flexible (D).¹⁹ A detailed knowledge of the thermodynamic profile allows for categorization of a binding event with respect to these four scenarios and

affects the design of ligands. The enthalpic and entropic contributions to these intermolecular associations, fundamental for characterizing the thermodynamic profile of an




Fig. 1 The four types of receptor–ligand interactions. (A) Rigid receptor, rigid ligand. (B) Rigid receptor, flexible ligand. (C) Flexible receptor, rigid ligand. (D) Flexible receptor, flexible ligand.

^aUniversity of Basel, Institute of Molecular Pharmacy, Pharmacenter of the University of Basel, Klingelbergstrasse 50, 4056, Basel, Switzerland. E-mail: beat.ernst@unibas.ch

^bDepartment of Chemistry, University of Connecticut, 55 N. Eagleville Road U3060, Storrs, CT, 06279 USA. E-mail: mark.peczuh@uconn.edu

^cUniversity of Basel, Biozentrum: Focal Area Structural Biology, Klingelbergstrasse 70, 4056 Basel, Switzerland

† Electronic supplementary information (ESI) available. See DOI: 10.1039/c7sc04289b

‡ These authors contributed equally to this work.



association, can be determined by isothermal titration calorimetry (ITC).

In the present study, an example of a receptor–ligand interaction according to type B (Fig. 1) was studied in detail. The receptor is the lectin FimH, located at the tip of bacterial pili. It mediates the attachment of uropathogenic *E. coli* (UPEC) to urothelial cells of the mammalian host and therefore represents the first step of the process leading to urinary tract infection (UTI).^{20–22} This adhesion impedes the clearance of bacteria from the urinary tract and is therefore essential for the infection of urothelial cells.^{23–25} Since the physiological ligand of FimH is the highly mannosylated glycoprotein uroplakin 1A located on urothelial cells,^{20–22} a broad variety of mannose-based FimH antagonists have been developed for blocking this interaction and thereby the bacterial infection of bladder cells.^{26–34} Their successful application in a UTI mouse model clearly supports their therapeutic potential for treatment and prevention of UTI.^{26,31,35}

To date, only the aglycone of mannosidic FimH antagonists has been successfully varied,^{26–37} whereas the replacement of mannose by other hexoses, *e.g.* D-glucose or D-galactose, led to a severe reduction or even loss of affinity.³⁸ We were interested to know whether septicose derivatives, *i.e.* seven-membered ring homologs of pyranoses,³⁹ could be utilized as ring-expanded FimH antagonists. Our interest was motivated by previous studies where the jackbean lectin concanavalin A (ConA) bound methyl septicoses in its carbohydrate binding pocket, albeit with reduced affinity relative to the pyranose ligand.^{40,41} ConA naturally recognizes the α 1-3, α 1-6-dimannosylmannose⁴² as well as methyl α -pyranosides of mannose and glucose.^{43,44} In contrast to the natural selectivity for α -configured saccharides, methyl β -septicoses were bound by ConA whereas α -septicoses were not.

Here we report results from an investigation of septicoses binding to the isolated lectin domain of FimH (FimH_{LD}), which is locked in the high-affinity state.^{45,46} Flexibility was fundamentally important for binding of the best seven-membered ring ligand, 2-*O*-*n*-heptyl-1,6-anhydro-D-glycero-D-galactitol (7) (informally referred to as 2-*O*-*n*-heptyl-1-deoxy-septicose), as FimH_{LD} selected one conformation among those on its shallow conformational energy surface.


Results

Synthesis of septicose ligands

The design of the septicose ligands was guided by the structure of the mannose-binding pocket of FimH. It consists of a deep pocket lined with polar amino acid residues forming an extended H-bond network with the natural ligand. The entrance to the mannose-binding pocket, the so-called “tyrosine gate”, is furnished with two tyrosines and an isoleucine and interacts with aliphatic or aromatic aglycones of FimH antagonists.³⁸ For mimicking mannose-based FimH antagonists, methyl β -D-glycero-D-galacto-septicoses 3 and 4 along with the related 1,6-anhydro-D-glycero-D-galactitols 5–7 were synthesized (3 and 4 will be referred to as methyl septicoses, and 5–7 as 1-deoxy-septicoses). For all these seven-membered ring analogs of α -D-mannose, the configuration at C3 to C6 (septicose numbering) is identical to the configuration at C2 to C5 in D-

mannose. In addition, the *n*-heptyl substituent on the C2 hydroxyl group of septicose 4 and 7 was expected to mimic the *n*-heptyl aglycone at the anomeric center (C1) of α -D-mannopyranoside 2 (Scheme 1).

For the syntheses of 3 & 4 and 6 & 7, acetonide protected oxepine 8 was utilized as a key starting material.⁴⁷ The previously described diastereoselective epoxidation and methanolysis of 8 provided methyl β -D-glycero-D-galacto-septicose 9 (84%).^{47,48} Alkylation of its C2 hydroxyl group gave 2-*O*-*n*-heptyl septicose 10 in 73% yield. By removal of the acetonide group on 9 and 10, methyl septicoses 3 and 4 were obtained in 93% and 82% yields, respectively. The preparation of 6 and 7 relied on the regio- and diastereoselective hydroboration–oxidation of 8 to give 11 (65%).⁴⁹ Deprotection of 1-deoxy-septicose 11 then yielded 6 (90%). Alternatively, 7 was obtained by alkylation of 11 at C2 to form compound 12 followed by deprotection (77% over two steps).



Scheme 1 Syntheses of FimH antagonists with a septicose core as replacement for α -D-mannopyranoside 1 and 2. Methyl β -septicose 3 and 1,2-di-deoxy-septicose 5 have been previously described.⁴⁰



Table 1 Affinity (IC_{50} & K_D) and thermodynamic data for the interaction of mannosides 1 & 2, septanosides 3 & 4 and 1-deoxy-septanoses 5–7 with $FimH_{LD}$

Compound	IC_{50}^a [μM]	K_D^b [μM]	ΔG_{obs}^b [$kJ mol^{-1}$]	ΔH_{obs}^b [$kJ mol^{-1}$]	$-T\Delta S_{obs}^b$ [$kJ mol^{-1}$]	N^b
1 (methyl α -D-mannoside)	5.6 ± 0.5	n.d.				
2 (<i>n</i> -heptyl α -D-mannoside)	0.064 ± 0.02	0.029	-43.0	-50.3	7.3	1.00
3	31.6 ± 4.2	n.d.				
4	2.83 ± 0.4	2.20	-32.3	-27.9	-4.4	0.98
5	86.8 ± 7.9	n.d.				
6	421 ± 30.5	n.d.				
7	1.37 ± 0.3	0.26	-37.5	-49.4	11.8	1.00

^a IC_{50} values were measured in a competitive binding assay.³⁶ ^b K_D values and thermodynamic parameters were determined by ITC experiments at a temperature of 25 °C.

Competitive binding assay

Compounds 1–7, along with other analogs (see ESI†), were evaluated for their binding to $FimH_{LD}$. Compounds were first screened in a competitive binding assay,³⁶ where a polymeric oligomannose–biotin conjugate coupled *via* streptavidin to horseradish peroxidase is added simultaneously with a serial dilution of the test ligand to wells coated with $FimH_{LD}$. After incubation, the peroxidase substrate 3,3',5,5'-tetramethylbenzidine is added and the binding is quantified by colorimetric detection. For the compounds 1–7, the competitive binding assay revealed IC_{50} values ranging from 64 nM to ~400 μM (Table 1). The addition of an *n*-heptyl substituent at C2 of 3 (→ 4) and 6 (→ 7) led to significantly improved inhibition. Septanoside 4 exhibits an 11-fold increase in affinity over 3, and 1-deoxy-septanose 7 a 307-fold improvement over 6. Thus, the *n*-heptyl substituent in 4 and 7 likely mimics the aglycone of the corresponding pyranoside 2.

ITC experiments with compounds 2, 4 and 7

Isothermal titration calorimetry (ITC) provided a deeper insight into the nature of the intermolecular interaction of $FimH_{LD}$ with 2-*n*-heptyl-septanoside 4 and 2-*n*-heptyl-1-deoxy-septanose 7 in comparison with *n*-heptyl α -D-mannopyranoside (2). All

three test compounds contain an *n*-heptyl unit – either as aglycone (→ 2) or as substituent in the 2-position (→ 4 and 7, respectively). The *n*-heptyl group is essential to establish the important hydrophobic contacts within the tyrosine gate. The K_D values obtained from ITC experiments were in relative agreement with the IC_{50} values from the competitive binding assay, *i.e.* in both assays 2 was the strongest binder followed by 7 and then 4 (Table 1).

ITC data (Table 1 and Fig. 2A) revealed that the almost 100-fold loss in affinity of compound 4 compared to compound 2 is due to a diminished enthalpic contribution (ΔH_{obs}^b) that is partly compensated by a more favorable entropy term ($T\Delta S_{obs}^b$). The less beneficial enthalpy term for septanoside 4 likely results from an increased desolvation penalty due to its increased polar surface area (108.6 Å for 4 compared to 99.4 Å for 2)⁵⁰ as well as from looser interactions with the $FimH_{LD}$. As a consequence of a looser fit, the flexibility of septanoside 4 is less compromised, explaining the substantially improved entropy term by 11.7 $kJ mol^{-1}$ (Table 1).

In contrast, the binding enthalpies of 2 and 7 are almost identical, so that the affinity loss of 1-deoxy-septanose 7 in comparison to mannoside 2 is exclusively due to a significant entropic penalty ($T\Delta S_{obs}^b$ term). According to eqn (1), the entropy ΔS° consists of desolvation entropy ΔS_{solv}° ,




Fig. 2 (A) Thermodynamic fingerprints of compounds 2, 4, and 7 binding to $FimH_{LD}$. (B) Heat capacity (ΔC_p) of compounds 2 and 7 binding to $FimH_{LD}$ from ITC experiments performed at three different temperatures (details in ESI†).



Table 2 Dissected entropic contributions of mannoside 2 and 1-deoxy-septanose 7 binding to FimH_{LD} at 298.15 K

Contributor	Mannoside 2 [kJ mol ⁻¹]	1-Deoxy-septanose 7 [kJ mol ⁻¹]
$-T\Delta S_{\text{solv}}^{\circ}$	-69.1	-68.8
$-T\Delta S_{\text{conf}}^{\circ}$	66.4	70.6
$-T\Delta S_{\text{mix}}^{\circ}$	10.0	10.0
$-T\Delta S_{\text{obs}}^{\circ}$	7.3	11.8

conformational entropy $\Delta S_{\text{conf}}^{\circ}$, and a term $\Delta S_{\text{mix}}^{\circ}$ reflecting the loss in translational and rotational degrees of freedom of both binding partners upon complex formation. Because $\Delta S_{\text{mix}}^{\circ}$ for the two antagonists is equal (10 kJ mol⁻¹, eqn (2), where R is the universal gas constant and 55.6 the molarity of water in [M]),^{51,52} the entropy penalty originates exclusively from a loss of conformational flexibility ($\Delta S_{\text{conf}}^{\circ}$) – either caused by the ligand and/or the receptor.

$$\Delta S_{\text{obs}}^{\circ} = \Delta S_{\text{solv}}^{\circ} + \Delta S_{\text{conf}}^{\circ} + \Delta S_{\text{mix}}^{\circ} \quad (1)$$

$$\Delta S_{\text{mix}}^{\circ} = R \ln\left(\frac{1}{55.6}\right) \quad (2)$$

To quantify the contributions of $\Delta S_{\text{solv}}^{\circ}$ and $\Delta S_{\text{conf}}^{\circ}$, ITC experiments were conducted at three different temperatures to determine the heat capacity (ΔC_p) of mannoside 2 and 1-deoxy-septanose 7 (Fig. 2B and Table 2). ΔC_p (eqn (3)), reporting on the entropy contributions from desolvation of ligand and protein, is equal for both complex formations (Fig. 2B). Since at 385 K, $\Delta S_{\text{solv}}^{\circ}$ reaches zero, *i.e.* the hydration shell no longer exists, $\Delta S_{\text{solv}, 298 \text{ K}}^{\circ}$ can be calculated according to eqn (4).⁵²⁻⁵⁴

$$\Delta C_p = \left(\frac{\partial \Delta H_{\text{obs}}^{\circ}}{\partial T} \right) \quad (3)$$

$$\Delta S_{\text{solv}, 298.15 \text{ K}}^{\circ} = \Delta C_p \ln\left(\frac{298.15 \text{ K}}{385 \text{ K}}\right) \quad (4)$$

The identical ΔC_p values (0.902 kJ K⁻¹ \pm 0.018 and 0.907 kJ K⁻¹ \pm 0.016, respectively) obtained for the interaction of FimH_{LD} with 1-deoxy-septanose 7 and mannoside 2 are a clear indication that both complex formations release comparable numbers of water molecules leading to a comparable gain of desolvation entropy $\Delta S_{\text{solv}}^{\circ}$. Consequently, the entropic penalty for 7 originates from a loss of conformational freedom of either the ligand and/or the protein upon binding (Table 2).

To comprehensively interpret the thermodynamics of binding, additional information regarding solution and bound conformations of mannoside 2 and 1-deoxy-septanose 7 are indispensable. The conformational flexibility of septanoses *vs.* pyranoses as well as the *n*-heptyl aglycone deserves special attention in this regard. Furthermore, the degree of conformational flexibility of FimH_{LD} has to be addressed. Finally, structural analysis by X-ray crystallography to elucidate the hydrogen

bond network established by the two ligands is essential for a final assessment of the two binding processes.

In silico comparison of the solution conformation of mannoside 2 and 1-deoxy-septanose 7

The large conformational entropy penalty for 1-deoxy-septanose 7 in comparison to mannoside 2 could be related to the extent of flexibility of their respective solution conformations. Therefore, the dynamic behavior in solution of each was studied by monitoring two collected variables using metadynamics simulations. The collected variables were defined as the angle between O1–C1–C4 and the dihedral torsion of O1–C1–O5–C5 for mannoside 2 and the corresponding angle O2–C2–C5 and dihedral torsion O2–C2–C1–O6 for compound 7 (for numbering see Fig. 3). Metadynamics simulations revealed an energy landscape for mannoside 2 with one distinct minimum of $-154.8 \text{ kJ mol}^{-1}$ of 99° for the angle O1–C1–C4 and 54° for the dihedral angle (indicated by a circle in Fig. 3A), whereas the energy surface for 1-deoxy-septanose 7 was much shallower, showing two minima of $-90.4 \text{ kJ mol}^{-1}$ at 99° and 36°, and $-89.5 \text{ kJ mol}^{-1}$ at 90° and 90°, respectively (indicated by circles in Fig. 3B). Thus, the metadynamic simulations clearly indicate that 1-deoxy-septanose 7 exhibits a much larger ring flexibility in comparison to mannoside 2. In addition, the minima observed in the metadynamics simulations coincide closely with the bound conformation of the crystal structure. However, compound 7 shows an additional minimum that does not overlap with the bound conformation and therefore adds to the entropic loss.

To further quantify the flexibility issue, all ring conformations were normalized to their respective global minimum. Cumulative frequency analysis revealed that compound 7 exhibits 23 accessible conformations within 16 kJ mol⁻¹ corresponding to the energy range of a hydrogen bond, whereas compound 2 has only access to 3 conformations. When a 44 kJ mol⁻¹ energy range is taken into consideration (equal to the highest barrier in a cyclohexane ring-flip), compound 7 has access to 72 conformations in contrast to the rather rigid mannoside 2 with only 14 accessible conformations (Fig. 3C). In summary, the much higher number of conformations available to septanose derivative 7 results in a higher loss of conformational flexibility upon complexation to FimH and accounts for the difference in entropies of binding to FimH_{LD} for 7 compared to 2.

Ab initio calculations involving interactions of the *n*-heptyl group

The preference of 1-deoxy-septanose 7 to position its *n*-heptyl tail in an axial orientation was demonstrated qualitatively by solution NMR experiments in the absence of protein. Karplus analysis of coupling constants $^3J_{2,3}$ and $^3J_{3,4}$ (septanose numbering) of 7 obtained from a 1D ¹H NMR spectrum at 900 MHz indicated torsion angles in agreement with those expected for the axial conformation (see ESI† for details). To assess whether the tyrosine gate affects the *n*-heptyl tail in 2 and 7 identically, non-covalent interaction energies were calculated based on the available crystal structures (*cf.* Fig. 5) with






Fig. 3 (A, B) Energy surface diagrams of the solution conformation of **2** (A) and **7** (B) obtained from metadynamics analysis. Circles represent the distinct minima observed in metadynamic simulations and crosses indicate the bound conformations in the crystal structures [PDB code 4BUQ (A) & 5CGB (B)]. Energies are given in kJ mol^{-1} and are color-coded from bordeaux-red (0 kJ mol^{-1}) to dark-blue (-150 kJ mol^{-1}). Vertical axes describe the observed dihedral angle (red), horizontal axes the observed angle (blue), both indicated in the structures to the right. (C) Cumulative frequency distribution analysis of all conformations (within 80 kJ mol^{-1} from the global minimum). Dashed lines indicate examples that occur at similar energies as denoted in the text.




Fig. 4 NMR chemical shift perturbation experiments of FimH_{LD} with mannoside 2 and 1-deoxy-septanose 7. ^1H , ^{15}N -HSQC spectra of FimH_{LD} in the absence of antagonist (green) and in the presence of an excess of 2 (blue) and 7 (magenta). Important residues in the binding sites are shown in detail on the panel at the right.

Jaguar.^{55–57} For the proper quantification of the non-covalent interactions, we performed *ab initio* DFT calculations using the B3LYP-MM functional in combination with the cc-pVQZ++ basis-set in the gas phase. The calculations led to comparable interaction energies of $-18.5 \text{ kJ mol}^{-1}$ and $-19.2 \text{ kJ mol}^{-1}$ for the *n*-heptyl tails of 2 and 7 with the tyrosine-gate. We therefore assume that their contributions to enthalpy as well as entropy are of comparable size.

Conformation of FimH_{LD} upon binding of ligand 2 and 7 assessed by NMR CSP experiments

NMR chemical shift perturbation (CSP) experiments of the FimH_{LD} backbone amide resonances were used to assess the

conformation of the protein backbone.⁵⁸ Thus, ^1H , ^{15}N -HSQC experiments of uniformly ^{15}N -labeled FimH_{LD} (see ESI†) were conducted in the absence and presence of an excess of each ligand. The resonance assignment of FimH_{LD} was available from previous studies.^{58,59} For both antagonists 2 and 7, the set of protein residues of the mannose binding pocket (e.g. Ala2, Asp54 and Gln133) and a nearby loop (e.g. Thr134, Asn138, Asp141, Gln143) exhibited highly similar CSP effects (Fig. 4; see also Fig. S5 in ESI†). The absence of line broadening effects demonstrates that the protein is rather rigid in complex with both antagonists. Furthermore, the almost identical signals for amino acids remote from the mannose-binding pocket indicate that FimH_{LD} does not undergo global conformational adaptions




Fig. 5 (A) Co-crystal structure of FimH_{LD} with mannoside 2 (PDB code 4BUQ) and (B) co-crystal structure of FimH_{LD} with 1-deoxy-septanose 7 (PDB code 5CGB); the intermolecular hydrogen bond network is depicted by dashed lines.

upon ligand binding. Thus, we can assume that the protein conformation upon binding mannoside 2 and 1-deoxyseptanose 7 is highly similar, consistent with the comparable thermodynamic outcomes of the interactions.

Crystal structure of FimH_{LD} in complex with mannoside 2 and 1-deoxyseptanose 7

The previously reported co-crystal structure of mannoside 2–FimH_{LD}⁶⁰ (PDB code 4BUQ, Fig. 5A) and the new high-resolution X-ray structure of FimH_{LD} co-crystallized with 7 (PDB code 5CGB; Fig. 5B and Table S3 in ESI†) exhibit a surprisingly high structural similarity with a backbone RMSD of 0.2 Å. Noteworthy, the well-defined, tight FimH mannose-binding pocket installs identical hydrogen bond networks with mannoside 2 and 1-deoxyseptanose 7 (Fig. 5). For both ligands, nine hydrogen bonds with the side-chains of the residues Asn46, Asp54, Gln133, Asn135 and Asp140, and to the backbone of Phe1 and Asp47 are formed (for statistics on diffraction data and structure refinement of ligand 7–FimH_{LD} complex see ESI†).

The dynamic stability of the hydrogen bond networks was assessed by MD simulations starting from the conformations of compound 2 and 7 from the crystal structures in Fig. 5. The simulations were run for the duration of 4.8 ns, followed by an analysis of the hydrogen bond network, where the occupancy of a given hydrogen bond interaction was monitored. The crucial hydrogen bonds with Phe1, Asp54 and Gln133 were retained with comparable occupancies by both compounds 2 and 7 (see Table S3 in ESI†). Therefore, in accordance with ITC experiments, enthalpic contributions from ligand–protein interactions can be predicted to be of similar size.

Discussion

The bacterial lectin FimH mediates the adhesion of uropathogenic *E. coli* to the bladder epithelium of its host. FimH_{LD} consists of a mannose-binding pocket, which is reached through a hydrophobic cleft equipped with two tyrosines and an isoleucine (tyrosine gate). Its high affinity interaction with mannoside 2 is achieved by an extended hydrogen bond network established between the mannose moiety and the carbohydrate recognition domain of the lectin and by hydrophobic σ–π interactions of the *n*-heptyl aglycone with the tyrosine gate.^{38,58,61} Replacement of the mannose moiety by other hexoses, *e.g.* D-glucose or D-galactose, leads to a substantial reduction or even loss of binding affinity.³⁸

Seven-membered ring analogs designed to mimic α-D-mannopyranosides in general exhibit reduced affinities for FimH_{LD}. From a series of septanoses and analogs, methyl septanose 4 and 1-deoxyseptanose 7 were identified as the best representative binders. The *n*-heptyl substituent on their 2-position enables σ–π stacking interaction with the tyrosine gate in analogy to mannoside 2.^{58,61} Nevertheless, 4 (2.2 μM) and 7 (260 nM) showed a 75- and 9-fold loss of inhibitory potency compared to mannoside 2 (29 nM).

To explain the large difference in affinity, a comparison of the thermodynamic fingerprints of their interactions with

FimH_{LD} turned out to be instructive. The ITC profile of *n*-heptyl mannoside (2) served as reference. Binding of 2, like many other mannoside-based antagonists, is largely enthalpy-driven with a major contribution by the nine hydrogen bonds formed between the mannose moiety and the lectin.^{29,35,38,58} The severe drop in affinity of methyl septanose 4 compared to mannoside 2 is predominantly due to a substantially smaller enthalpy term ($\Delta\Delta H_{\text{obs}}^{\circ} = 22.4 \text{ kJ mol}^{-1}$), accompanied by a pronounced improvement of the entropy term ($-T\Delta\Delta S_{\text{obs}}^{\circ} = 11.7 \text{ kJ mol}^{-1}$). One possible explanation for the severe enthalpy penalty is a steric clash induced by the methoxy group in the 1-position, disordering the essential hydrogen bond network. A less well-defined hydrogen bond network on the other hand would be consistent with an entropy gain of 4 in comparison to mannoside 2 because of the increased conformational flexibility. Interestingly, the almost identical enthalpy terms for mannoside 2 and 1-deoxyseptanose 7 ($\Delta H_{\text{obs}}^{\circ} \sim -50 \text{ kJ mol}^{-1}$) suggest that FimH adopts very similar conformations enabling the formation of all critical hydrogen bonds to both ligands, a hypothesis supported by solution NMR and X-ray co-crystallography.

The origin for the reduced affinity of 7 compared to 2 is a significantly higher entropic penalty. ITC measurements at different temperatures revealed almost identical heat capacities ΔC_p for both mannoside 2 and 1-deoxyseptanose 7, indicating comparable desolvation entropies ($\Delta S_{\text{solv}}^{\circ}$). Since $\Delta S_{\text{mix}}^{\circ}$ reflecting the loss in translational and rotational degrees of freedom upon complex formation can be assumed to be identical, the increased entropic penalty for 7 can be attributed solely to a reduced conformational freedom of the ligand and/or the protein. With NMR chemical shift perturbation experiments it was shown that 1-deoxyseptanose 7 exhibited comparable chemical shift changes and line widths for amino acid residues of the FimH binding pocket as mannoside 2. Thus, both ligands form comparable complexes with FimH_{LD} and therefore exhibit comparable $\Delta S_{\text{conf}}^{\circ}$ terms. Quantum-mechanical calculations revealed almost identical contributions of the aglycones of 2 and 7 to the interaction energy, suggesting that the loss of conformational entropy is solely due to the higher flexibility of the seven-membered ring of 7 compared to the six-membered ring of 2 in solution. Upon binding to FimH_{LD}, a specific conformation of the septanose ring is required, leading to a significant rigidification of the compound relative to its unbound state. Metadynamics simulations, revealing a flat energy profile for 1-deoxyseptanose 7 with various ring conformations separated by relatively low energetic barriers, support this assumption.

The bound conformation of 7 can therefore be regarded as the result of a conformational selection of the ligand. Whereas conformational selection in terms of protein dynamics has been widely described and quantified by the use of NMR dynamics experiments of the protein,^{7,15–18} a quantitative description of the impact of ligand flexibility on the thermodynamics of binding is still rare, likely due to the numerous contributing factors, which could be separated and analyzed in this specific example.



Conclusions

ITC results, NMR CSP experiments, computational considerations, and X-ray crystallographic data support the conclusion that 2-*n*-heptyl 1-deoxy-septanose 7 adopts a conformation enabling the formation of a H-bond network with FimH_{LD} identical to the corresponding mannoside 2. Furthermore, the loss of affinity of 7 is almost exclusively due to a loss in conformational entropy ΔS_{conf} . *In silico*-analysis and solution NMR data ultimately showed that, although the main solution conformation of the seven-membered ring is similar to the bound conformation, the pronounced flexibility of the ring in solution causes significant entropic penalties upon complex formation.

In view of this result, the evaluation of glycomimetics should always include thermodynamic profiling because the quantification of enthalpic and entropic terms can be highly informative for the design of improved antagonists. In the case of FimH antagonists, 1-deoxy-septanose 7 provides an excellent manopyranoside mimic, *i.e.* can establish an identical H-bond network as the parent compound. However, it suffers from a substantial entropic penalty due to rigidification of the inherent ring flexibility upon complexation. This study excellently exemplifies that flexibility can be an important element in the design of small molecule ligands of target proteins.^{62,63}

Conflicts of interest

There are no conflicts to declare.

Acknowledgements

We thank Prof. Stephan Grzesiek at the Biozentrum, University of Basel for the access to 600 and 900 MHz NMR spectrometers. The financial support by the Swiss National Science Foundation (CS & PZ: Swiss National Science Foundation (SNF) grant 200020_129935; RP: SNF grant 200020_146202; TM: SNF grant R'EQUIP 145023) is gratefully acknowledged. B. F. thanks the German Academic Exchange Service (DAAD) for a stipendship. Finally, support for this work was provided to MWP by the National Science Foundation (CAREER CHE-0546311).

Notes and references

- 1 S. Moghaddam, Y. Inoue and M. K. Gilson, *J. Am. Chem. Soc.*, 2009, **131**, 4012.
- 2 E. Fischer, *Ber. Dtsch. Chem. Ges.*, 1894, **27**, 2985.
- 3 F. W. Lichtenthaler, *Angew. Chem., Int. Ed.*, 1995, **33**, 2364.
- 4 R. U. Lemieux and U. Spohr, *Adv. Carbohydr. Chem. Biochem.*, 1994, **50**, 1.
- 5 D. E. Koshland, *Angew. Chem., Int. Ed.*, 1995, **33**, 2375.
- 6 P. W. Snyder, J. Mecinovic, D. T. Moustakas, S. W. Thomas III, M. Harder, E. T. Mack, M. R. Lockett, A. Heroux, W. Sherman and G. M. Whitesides, *Proc. Natl. Acad. Sci. U. S. A.*, 2011, **108**, 17889.

- 7 C. Diehl, O. Engstrom, T. Delaine, M. Hakansson, S. Genheden, K. Modig, H. Leffler, U. Ryde, U. J. Nilsson and M. Akke, *J. Am. Chem. Soc.*, 2010, **132**, 14577.
- 8 F. Marcelo, Y. He, S. A. Yuzwa, L. Nieto, J. Jiménez-Barbero, M. Sollogoub, D. J. Vocadlo, G. D. Davies and Y. Bleriot, *J. Am. Chem. Soc.*, 2009, **131**, 5390.
- 9 A. R. Patel, G. Ball, L. Hunter and F. Liu, *Org. Biomol. Chem.*, 2013, **11**, 3781.
- 10 D. D. Staas, K. L. Savage, V. L. Sherman, H. L. Shimp, T. A. Lyle, L. O. Tran, C. M. Wiscount, D. R. McMasters, P. E. Sanderson, P. D. Williams, B. J. Lucas Jr, J. A. Krueger, S. D. Lewis, R. B. White, S. Yu, B. K. Wong, C. J. Kochansky, M. R. Anari, Y. Yan and J. P. Vacca, *Bioorg. Med. Chem.*, 2006, **14**, 6900.
- 11 Y. Endo, S. Takehana, M. Ohno, P. E. Driedger, S. Stabel, M. Y. Mizutani, N. Tomioka, A. Itai and K. Shudo, *J. Med. Chem.*, 1998, **41**, 1476.
- 12 Y. Endo, M. Ohno, M. Hirano, A. Itai and K. Shudo, *J. Am. Chem. Soc.*, 1996, **118**, 1841.
- 13 K. Gunasekaran and R. Nussinov, *J. Mol. Biol.*, 2007, **365**, 257.
- 14 D. Rauh, G. Klebe and M. T. Stubbs, *J. Mol. Biol.*, 2004, **335**, 1325.
- 15 D. D. Boehr, R. Nussinov and P. E. Wright, *Nat. Chem. Biol.*, 2009, **5**, 789.
- 16 K. Okazaki and S. Takada, *Proc. Natl. Acad. Sci. U. S. A.*, 2008, **105**, 11182.
- 17 I. V. Nesmelova, E. Ermakova, V. A. Daragan, M. Pang, M. Menendez, L. Lagartera, D. Solis, L. G. Baum and K. H. Mayo, *J. Mol. Biol.*, 2010, **397**, 1209.
- 18 T. R. Weikl and F. Paul, *Protein Sci.*, 2014, **23**, 1508.
- 19 C. H. Reynolds and M. K. Holloway, *ACS Med. Chem. Lett.*, 2011, **2**, 433.
- 20 X. R. Wu, T. T. Sun and J. J. Medina, *Proc. Natl. Acad. Sci. U. S. A.*, 1996, **93**, 9630.
- 21 G. Zhou, W. J. Mo, P. Sebbel, G. Min, T. A. Neubert, R. Glockshuber, X. R. Wu, T. T. Sun and X. P. Kong, *J. Cell Sci.*, 2001, **114**, 4095.
- 22 B. Xie, G. Zhou, S. Y. Chan, E. Shapiro, X. P. Kong, X. R. Wu, T. T. Sun and C. E. Costello, *J. Biol. Chem.*, 2006, **281**, 14644.
- 23 A. Ronald, *Am. J. Med.*, 2002, **113**, 14.
- 24 D. Abgottspoon, G. Rölli, L. Hosch, A. Steinhuber, X. Jiang, O. Schwardt, B. Cutting, M. Smieško, U. Jenal, B. Ernst and A. Trampuz, *J. Microbiol. Methods*, 2010, **82**, 249.
- 25 M. Scharenberg, D. Abgottspoon, E. Cicek, X. Jiang, O. Schwardt, S. Rabbani and B. Ernst, *Assay Drug Dev. Technol.*, 2011, **9**, 455.
- 26 T. Klein, D. Abgottspoon, M. Wittwer, S. Rabbani, J. Herold, X. Jiang, S. Kleeb, C. Luthi, M. Scharenberg, J. Bezençon, E. Gubler, L. Pang, M. Smieško, B. Cutting, O. Schwardt and B. Ernst, *J. Med. Chem.*, 2010, **53**, 8627.
- 27 O. Schwardt, S. Rabbani, M. Hartmann, D. Abgottspoon, M. Wittwer, S. Kleeb, A. Zalewski, M. Smieško, B. Cutting and B. Ernst, *Bioorg. Med. Chem.*, 2011, **19**, 6454.
- 28 X. Jiang, D. Abgottspoon, S. Kleeb, S. Rabbani, M. Scharenberg, M. Wittwer, M. Haug, O. Schwardt and B. Ernst, *J. Med. Chem.*, 2012, **55**, 4700.



29 L. Pang, S. Kleeb, K. Lemme, S. Rabbani, M. Scharenberg, A. Zalewski, F. Schadler, O. Schwardt and B. Ernst, *ChemMedChem*, 2012, **7**, 1404.

30 M. Aronson, O. Medalia, L. Schori, D. Mirelman, N. Sharon and I. Ofek, *J. Infect. Dis.*, 1979, **139**, 329.

31 C. K. Cusumano, J. S. Pinkner, Z. Han, S. E. Greene, B. A. Ford, J. R. Crowley, J. P. Henderson, J. W. Janetka and S. J. Hultgren, *Sci. Transl. Med.*, 2011, **3**, 109ra115.

32 D. Abgottspoon and B. Ernst, *Chimia*, 2012, **66**, 166.

33 M. Totsika, M. Kostakioti, T. J. Hannan, M. Upton, S. A. Beatson, J. W. Janetka, S. J. Hultgren and M. A. Schembri, *J. Infect. Dis.*, 2013, **208**, 921.

34 J. Bouckaert, Z. Li, C. Xavier, M. Almant, V. Caveliers, T. Lahoutte, S. D. Weeks, J. Kovensky and S. G. Gouin, *Chem.-Eur. J.*, 2013, **19**, 7847.

35 S. Kleeb, L. Pang, K. Mayer, D. Eriş, A. Sigl, R. C. Preston, P. Zihlmann, T. Sharpe, R. P. Jakob, D. Abgottspoon, A. S. Hutter, M. Scharenberg, X. Jiang, G. Navarra, S. Rabbani, M. Smieško, N. Lüdin, J. Bezençon, O. Schwardt, T. Maier and B. Ernst, *J. Med. Chem.*, 2015, **58**, 2221.

36 S. Rabbani, X. Jiang, O. Schwardt and B. Ernst, *Anal. Biochem.*, 2010, **407**, 188.

37 Z. Han, J. S. Pinkner, B. Ford, R. Obermann, W. Nolan, S. A. Wildman, D. Hobbs, T. Ellenberger, C. K. Cusumano, S. J. Hultgren and J. W. Janetka, *J. Med. Chem.*, 2010, **53**, 4779.

38 J. Bouckaert, J. Berglund, M. Schembri, E. De Genst, L. Cools, M. Wuhrer, C.-S. Hung, J. Pinkner, R. Slättegård, A. Zavialov, D. Choudhury, S. Langermann, S. J. Hultgren, L. Wyns, P. Klemm, S. Oscarson, S. D. Knight and H. De Greve, *Mol. Microbiol.*, 2005, **55**, 441.

39 J. Saha and M. W. Peczuh, *Adv. Carbohydr. Chem. Biochem.*, 2011, **66**, 121.

40 M. R. Duff Jr, W. S. Fyvie, S. D. Markad, A. E. Frankel, C. V. Kumar, J. A. Gascón and M. W. Peczuh, *Org. Biomol. Chem.*, 2011, **9**, 154.

41 S. Castro, M. Duff, N. L. Snyder, M. Morton, C. V. Kumar and M. W. Peczuh, *Org. Biomol. Chem.*, 2005, **3**, 3869.

42 D. Gupta, T. K. Dam, S. Oscarson and C. F. Brewer, *J. Biol. Chem.*, 1997, **272**, 6388.

43 M. C. Chervenak and E. J. Toone, *Biochemistry*, 1995, **34**, 5685.

44 F. P. Schwarz, K. D. Puri, R. G. Bhat and A. Surolia, *J. Biol. Chem.*, 1993, **268**, 7668.

45 D. Eriş, R. C. Preston, M. Scharenberg, F. Hulliger, D. Abgottspoon, L. Pang, X. Jiang, O. Schwardt and B. Ernst, *ChemBioChem*, 2016, **17**, 1012.

46 M. M. Sauer, R. P. Jakob, J. Eras, S. Baday, D. Eriş, G. Navarra, S. Bernèche, B. Ernst, T. Maier and R. Glockshuber, *Nat. Commun.*, 2016, **7**, 10738.

47 S. D. Markad, S. Xia, N. L. Snyder, B. Surana, M. D. Morton, C. M. Hadad and M. W. Peczuh, *J. Org. Chem.*, 2008, **73**, 6341.

48 M. P. DeMatteo, N. L. Snyder, M. Morton, D. M. Baldisseri, C. M. Hadad and M. W. Peczuh, *J. Org. Chem.*, 2005, **70**, 24.

49 R. Murali and M. Nagarajan, *Carbohydr. Res.*, 1996, **280**, 351.

50 P. Ertl, B. Rohde and P. Selzer, *J. Med. Chem.*, 2000, **43**, 3714.

51 B. M. Baker and K. P. Murphy, *J. Mol. Biol.*, 1997, **268**, 557.

52 K. P. Murphy, D. Xie, K. S. Thompson, L. M. Amzel and E. Freire, *Proteins*, 1994, **18**, 63.

53 K. P. Murphy, P. L. Privalov and S. J. Gill, *Science*, 1990, **247**, 559.

54 R. L. Baldwin, *Proc. Natl. Acad. Sci. U. S. A.*, 1986, **83**, 8069.

55 Schrödinger Suite 2015-4, Jaguar, Version 9.0, Schrödinger, LLC, New York, NY, 2015.

56 S. T. Schneebeli, A. D. Bochevarov and R. A. Friesner, *J. Chem. Theory Comput.*, 2011, **7**, 658.

57 A. D. Bochevarov, E. Harder, T. F. Hughes, J. R. Greenwood, D. A. Braden, D. M. Philipp, D. Rinaldo, M. D. Halls, J. Zhang and R. A. Friesner, *Int. J. Quantum Chem.*, 2013, **113**, 2110.

58 B. Fiege, S. Rabbani, R. C. Preston, R. P. Jakob, P. Zihlmann, O. Schwardt, X. Jiang, T. Maier and B. Ernst, *ChemBioChem*, 2015, **16**, 1235.

59 S. Vanwetswinkel, A. N. Volkov, Y. G. J. Sterckx, A. Garcia-Pino, L. Buts, W. F. Vranken, J. Bouckaert, R. Roy, L. Wyns and N. A. J. van Nuland, *J. Med. Chem.*, 2014, **57**, 1416.

60 G. Roos, A. Wellens, M. Touaibia, N. Yamakawa, P. Geerlings, R. Roy, L. Wyns and J. Bouckaert, *ACS Med. Chem. Lett.*, 2013, **4**, 1085.

61 A. Wellens, M. Lahmann, M. Touaibia, J. Vaucher, S. Oscarson, R. Roy, H. Remaut and J. Bouckaert, *Biochemistry*, 2012, **51**, 4790.

62 S. Chung, J. B. Parker, M. Bianchet, L. M. Amzel and J. T. Stivers, *Nat. Chem. Biol.*, 2009, **5**, 407.

63 S. A. Moura-Tamames, M. J. Ramos and P. A. Fernandes, *J. Mol. Graphics Modell.*, 2009, **27**, 908.

